Over two percent of adult patients now take a GLP-1 drug to treat overweight or obesity, according to newly released FAIR ...

New data from digital marketing agency Sagapixel reveals that public interest in the term “GLP-1” has officially surpassed search volume for “Ozempic” — marking a fundamental shift in how patients ...

As Australia faces a turning point in obesity management, researchers from Monash University have contributed new insights ...

The average representation of GLP-1 drugs used for weight loss in total annual claims was 10.5% for 2025, an increase over ...

Veru's pivot with enobosarm: groundbreaking Phase 2b results enhance GLP-1 therapy outcomes. A positive launch could yield ...

In 2024, 4% of U.S. adults were prescribed a GLP-1 therapy — a 363.7% increase from 0.9% in 2019, according to a Fair Health analysis of more than 51 billion commercial claim records.  Fair Health ...

Newly recognized issues, including extreme fatigue with excessive weight reduction, bone loss, and abdominal pain, point to ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may cut the risk of obesity-related cancer (ORC) in patients being treated for diabetes and obesity.

For people trying to quit smoking, use of a GLP-1 receptor agonist may help prevent weight gain, a common barrier to quitting ...

If you're one of the millions of Americans who have used or thought about using GLP-1 weight-loss drugs, it’s important to ...

And GLP-1 agonists were associated with an 8% lower mortality risk as well (HR 0.92, 95% CI 0.87-0.97), according to findings ...

New review confirms psychiatric safety of commonly used glucagon-like peptide 1 receptor agonists among patients without ...